Deutsche Bank AG Purchases 109,281 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Deutsche Bank AG increased its stake in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 747.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 123,899 shares of the company’s stock after acquiring an additional 109,281 shares during the quarter. Deutsche Bank AG owned about 0.23% of Prelude Therapeutics worth $159,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Prelude Therapeutics during the fourth quarter valued at $26,000. JPMorgan Chase & Co. increased its stake in Prelude Therapeutics by 925.0% in the 4th quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock worth $78,000 after buying an additional 55,183 shares during the period. Rhumbline Advisers increased its stake in Prelude Therapeutics by 1,289.8% in the 4th quarter. Rhumbline Advisers now owns 166,830 shares of the company’s stock worth $213,000 after buying an additional 154,826 shares during the period. Marshall Wace LLP increased its stake in Prelude Therapeutics by 9.2% in the 4th quarter. Marshall Wace LLP now owns 392,155 shares of the company’s stock worth $498,000 after buying an additional 33,018 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Prelude Therapeutics by 222.2% during the 4th quarter. Renaissance Technologies LLC now owns 634,500 shares of the company’s stock worth $809,000 after acquiring an additional 437,600 shares in the last quarter. Institutional investors own 79.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PRLD shares. JMP Securities restated a “market outperform” rating and issued a $4.00 price target on shares of Prelude Therapeutics in a report on Tuesday, April 29th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Prelude Therapeutics in a report on Monday, May 5th.

Insider Buying and Selling

In other news, CEO Krishna Vaddi acquired 675,000 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was acquired at an average cost of $0.69 per share, with a total value of $465,750.00. Following the completion of the acquisition, the chief executive officer now owns 1,999,296 shares of the company’s stock, valued at $1,379,514.24. The trade was a 50.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Combs purchased 100,000 shares of the stock in a transaction dated Tuesday, March 25th. The shares were bought at an average cost of $0.69 per share, for a total transaction of $69,000.00. Following the completion of the purchase, the insider now owns 480,123 shares in the company, valued at approximately $331,284.87. This trade represents a 26.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 822,500 shares of company stock worth $568,475. Company insiders own 63.90% of the company’s stock.

Prelude Therapeutics Trading Up 2.4%

Shares of PRLD stock opened at $0.91 on Tuesday. The company’s 50-day moving average price is $0.82 and its 200-day moving average price is $0.92. The stock has a market cap of $51.21 million, a price-to-earnings ratio of -0.51 and a beta of 1.30. Prelude Therapeutics Incorporated has a twelve month low of $0.61 and a twelve month high of $6.80.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.05. As a group, equities research analysts predict that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.